AIMD

Ainos, Inc. (AIMD) | Rumor.io

Ainos

AIMD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,522

Bullish sentiment (50-day avg)85%

Price to earnings ratio-0.38

Market capitalization9.8M

Earnings per share-2.49

Dividend yield (TTM)—

Revenue (annual)124.2K

Net income (annual)-14.8M

Social

What share of all stock conversation is about AIMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 29

Ainos, Inc. has delivered 1,400 AI Nose systems to ASE under a $2.1 million, three-year contract, marking an important execution milestone.
The company is expected to generate revenue from Q3, and a larger second-phase deployment is under negotiation.
Ainos has reported Q2 2026 revenue of $11.5B, a 50% YoY increase, with gross margin rising to 54%.

Generated by AI

Sentiment

Of the messages about AIMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80% -20	85.71% -10.95	83.94% -6.94
Bearish	0%	20% new	14.29% +10.95	16.06% +6.94

Bullish· May 26

The volume for $AIMD was extremely high, with 5 million shares traded, suggesting strong investor interest.
The asset has the potential for significant long-term growth, with one analyst predicting it will be "much higher" in the future.
The stock has already demonstrated strong short-term gains, with one investor noting a 120% "boomerang" return after a 5M setup.

Bearish· Aug 6

$AIMD's recent price movement is stressful for traders, with some experiencing losses due to poor timing.
The stock's downtrend break requires it to regain $3.70 and hold there, with a need for a base to be established as soon as possible.
$AIMD is considered a pump and dump, and its high short percentage and overbought condition make it due for a stop loss raid to balance out.

Generated by AI

Topics

Of the messages about AIMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	81.76%
Analysts	0%	0%	0%	0.3%
Controversies	0%	0%	0%	0.3%
Earnings	0%	0%	0%	5.47%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	12.16%

Announcements· Aug 7

Ainos, Inc. (AIMD) has filed a Form 8-K with the SEC, citing an "other events" notice, on August 7, 2025.
The filing was accepted by the SEC at 4:17 AM EDT on the same day.
The stock price of AIMD increased by 39.91% following the announcement.

Technical Analysis· Aug 6

Scalping opportunities exist on daily levels, with the stock rejecting at support and potentially forming a rug.
The Perfect squeeze action was stalked through daily resistance, leading to an 8-day win streak; rules and emotions are in check.
A downtrend break needs to regain 3.70 and hold there; a base needs to be established as soon as possible to confirm the flip from supply to demand.

Generated by AI

Community

Of the messages about AIMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	73.15%	74.6%	56.29%
Newcomers	20%	26.85%	25.4%	43.71%

Regulars· Aug 6

The company's AI nose technology has been validated commercially by a leading semiconductor company, ASE Technology Holdings, with a $2.1 million order, which is expected to open many new doors for the company.
The stock has seen a significant spike, with a price of $4.50 at one point, and has been recommended to be loaded up on by the regulars, with a target price of $3.50-$4.
The contract news for $AIMD is relatively small but significant, as it marks the company's first revenue with a major player in the semiconductor industry, and the stock has been recommended to be loaded up on with a target price of $3.50-$4.

Newcomers· Sep 24

Ainos, Inc. (AIMD) has signed a license agreement with BioPhoenix for the VELDONA low-dose oral interferon alfa platform, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications.
The agreement includes a potential $10 million collaboration framework, with BioPhoenix getting an exclusive worldwide license to VELDONA for Sjögren's disease and thrombocytopenia.
The license deal could lead to additional revenue for Ainos, with the company retaining core platform ownership, product supply opportunities, and contractual participation in downstream commercial revenue.

Generated by AI

Gainers DNA X (NASDAQ:SONM) stock increased by 14.7% to $4.14 during Thursday's pre-market session. The company's market cap stands at $5.3 million. Ainos (NASDAQ:AIMD) stock rose 13.35% to $1.58. The market

5d agoBenzinga

Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework

("BioPhoenix"), establishing a collaboration framework with a potential aggregate value of $10 million. The framework comprises an initial license fee, conditional consideration for licenses covering 15 additional indications, and a one-time fee upon the first sublicense.

6d agoYahoo Finance

VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset

Report points to front-end semiconductor orders, a $2.VASRO highlighted two developments that it views as important markers in Ainos' semiconductor commercialization: the transition of its front-end semiconductor program from validation to initial commercial orders, and the expansion of its proprietary real-world chemical dataset beyond 1 billion records.

13d agoYahoo Finance

Ainos Shares Rise 6.9% After Receiving Initial AI Nose Semiconductor Orders

Ainos Inc. (NASDAQ:AIMD) shares rose 6.

15d agofinance.yahoo.com

Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing

Ainos is receiving initial commercial orders from a front-end semiconductor company.The milestone marks Ainos' progress toward commercial adoption in front-end semiconductor environments and represents a step toward the broader revenue-generation opportunities the Company is pursuing.

16d agoYahoo Finance

Ainos stock jumps on AI Nose orders from semiconductor sector

16d agoInvesting.com

Also Discussed

Investors talking about AIMD also mention

#	Name	Attention
1	SOBR Safe, Inc.SOBR	0%0
2	111, Inc. ADRYI	0%0
3	TPHS - Trinity Place Holdings Inc.	——
4	SGD - Safe and Green Development Corporation	——
5	MINM - Minim, Inc.	——
6	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
7	Veea Inc.VEEA	0%0
8	Nouveau Monde Graphite Inc.NMG	0%0
9	Wrap Technologies Inc.WRAP	0%0
10	SGE - Strong Global Entertainment, Inc.	——

Ainos, Inc.

Technology
Scientific & Technical Instruments

Ainos, Inc. is a dual-platform AI and biotechnology company focused on smelltech and immune therapeutics. Ainos, Inc. develops AI Nose, an electronic olfaction platform that uses AI and a smell language model to convert scent and volatile compounds into machine-readable Smell ID data. This technology is used in applications such as robotics, smart factories, semiconductor manufacturing, healthcare, senior care, and women’s health. The company also develops VELDONA, a low-dose oral interferon platform designed for human and animal health applications, including rare, autoimmune, and infectious disease programs. In addition, Ainos, Inc. works on point-of-care testing and related diagnostic products, positioning itself at the intersection of digital sensing, medical technology, and therapeutic development.

Website

Location

3050 Post Oak Boulevard

Houston, TX, 77056

United States

Social

What share of all stock conversation is about AIMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 29

Ainos, Inc. has delivered 1,400 AI Nose systems to ASE under a $2.1 million, three-year contract, marking an important execution milestone.
The company is expected to generate revenue from Q3, and a larger second-phase deployment is under negotiation.
Ainos has reported Q2 2026 revenue of $11.5B, a 50% YoY increase, with gross margin rising to 54%.

Generated by AI

Sentiment

Of the messages about AIMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80% -20	85.71% -10.95	83.94% -6.94
Bearish	0%	20% new	14.29% +10.95	16.06% +6.94

Bullish· May 26

The volume for $AIMD was extremely high, with 5 million shares traded, suggesting strong investor interest.
The asset has the potential for significant long-term growth, with one analyst predicting it will be "much higher" in the future.
The stock has already demonstrated strong short-term gains, with one investor noting a 120% "boomerang" return after a 5M setup.

Bearish· Aug 6

$AIMD's recent price movement is stressful for traders, with some experiencing losses due to poor timing.
The stock's downtrend break requires it to regain $3.70 and hold there, with a need for a base to be established as soon as possible.
$AIMD is considered a pump and dump, and its high short percentage and overbought condition make it due for a stop loss raid to balance out.

Generated by AI

Topics

Of the messages about AIMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	81.76%
Analysts	0%	0%	0%	0.3%
Controversies	0%	0%	0%	0.3%
Earnings	0%	0%	0%	5.47%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	12.16%

Announcements· Aug 7

Ainos, Inc. (AIMD) has filed a Form 8-K with the SEC, citing an "other events" notice, on August 7, 2025.
The filing was accepted by the SEC at 4:17 AM EDT on the same day.
The stock price of AIMD increased by 39.91% following the announcement.

Technical Analysis· Aug 6

Scalping opportunities exist on daily levels, with the stock rejecting at support and potentially forming a rug.
The Perfect squeeze action was stalked through daily resistance, leading to an 8-day win streak; rules and emotions are in check.
A downtrend break needs to regain 3.70 and hold there; a base needs to be established as soon as possible to confirm the flip from supply to demand.

Generated by AI

Community

Of the messages about AIMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	73.15%	74.6%	56.29%
Newcomers	20%	26.85%	25.4%	43.71%

Regulars· Aug 6

The company's AI nose technology has been validated commercially by a leading semiconductor company, ASE Technology Holdings, with a $2.1 million order, which is expected to open many new doors for the company.
The stock has seen a significant spike, with a price of $4.50 at one point, and has been recommended to be loaded up on by the regulars, with a target price of $3.50-$4.
The contract news for $AIMD is relatively small but significant, as it marks the company's first revenue with a major player in the semiconductor industry, and the stock has been recommended to be loaded up on with a target price of $3.50-$4.

Newcomers· Sep 24

Ainos, Inc. (AIMD) has signed a license agreement with BioPhoenix for the VELDONA low-dose oral interferon alfa platform, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications.
The agreement includes a potential $10 million collaboration framework, with BioPhoenix getting an exclusive worldwide license to VELDONA for Sjögren's disease and thrombocytopenia.
The license deal could lead to additional revenue for Ainos, with the company retaining core platform ownership, product supply opportunities, and contractual participation in downstream commercial revenue.

Generated by AI

Ainos

Social

Sep 29

Bullish· May 26

Bearish· Aug 6

Announcements· Aug 7

Technical Analysis· Aug 6

Regulars· Aug 6

Newcomers· Sep 24

12 Information Technology Stocks Moving In Thursday's Pre-Market Session - DNA X (NASDAQ:SONM), Ainos (NA

Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework

VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset

Ainos Shares Rise 6.9% After Receiving Initial AI Nose Semiconductor Orders

Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing

Ainos stock jumps on AI Nose orders from semiconductor sector

Also Discussed

Ainos, Inc.

Company Information

Location

12 Information Technology Stocks Moving In Thursday's Pre-Market Session - DNA X (NASDAQ:SONM), Ainos (NA

Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework

VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset

Ainos Shares Rise 6.9% After Receiving Initial AI Nose Semiconductor Orders

Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing

Ainos stock jumps on AI Nose orders from semiconductor sector

Also Discussed

Social

Sep 29

Bullish· May 26

Bearish· Aug 6

Announcements· Aug 7

Technical Analysis· Aug 6

Regulars· Aug 6

Newcomers· Sep 24